Roche reported mid‑stage results for CT‑388, a dual GLP‑1/GIP receptor agonist, showing about 22.5% placebo‑adjusted weight loss at 48 weeks in a ~469‑patient Phase 2 study and signaled plans to start Phase 3 testing by the end of March. The data underpinned Roche’s decision to advance the asset, which it acquired via the $2.7 billion Carmot deal, into pivotal development. Analysts cautioned the market will focus on discontinuation‑adjusted efficacy and the drug’s path to commercial relevance amid dominant competitors from Novo Nordisk and Eli Lilly.